Wednesday – Oracle
Last quarter Oracle’s (ORCL) long serving frontman Larry Ellison stepped down from his role as CEO and appointed 2 co-CEO successors. Heading into Oracle’s first quarter in the post-Ellison era Estimize community members are expecting the technology company to continue growing steadily and slightly outperform Wall Street’s earnings expectations.
Wednesday Estimize contributors are looking for a 1 cent gain in earnings per share while year over year revenue rises 3%. These results would maintain Oracle’s rate of sales expansion over the past 5 quarters and represent a slowing of profit growth to a rate between 1% and 2%.
Wednesday – FedEx
At one point this summer crude oil was trading at over $100 per barrel. As we enter the final stretch of the year that price has collapsed to just $56. As a major player in logistics FedEx’s (FDX) financial performance is greatly impacted by the price of oil, falling gas prices throughout the fall could provide FedEx an opportunity to post gains to its bottom line.
Over the past 3 months EPS estimates and revenue projections from both Estimize and Wall Street have been rising. With the final picture clearing up the Estimize community’s EPS forecast is settling at $2.16 per share, 2 cents lower than the Wall Street consensus, but still an impressive 38% higher than the number FedEx reported in the same quarter of last year.
On the top line Estimize analysts are calling for $11.99 billion which is marginally higher than Wall Street’s prediction and would mark a 5% improvement from last year’s total.
Posted by jackbassteam on December 17, 2014
UPLD : NASDAQ
Upland Software is a software consolidator that provides
a suite of cloud-based applications for Enterprise
Workforce Management. The company was founded in
2010 as Silverback Acquisition Corporation and is
headquartered in Austin, Texas.
Technology — Enterprise Software — Software as a Service
BEEN THERE, DONE THAT: ACT 2 OF A SUCCESSFUL TEAM, THIS TIME IN SOFTWARE; INITIATE AT BUY
Upland is a software consolidator in the enterprise work management space
that looks to us to be sufficiently inexpensively valued that the stock has the
potential to be quite rewarding over the long term. We are initiating coverage
with a BUY rating and a $15.00 price target.
What they do. Upland provides a cloud-based work management software
platform that enables businesses to plan, manage and execute projects and
tasks. The suite of enterprise work management applications enables
companies to better optimize the allocation and utilization of their
workforce, time, and money. The firm has more than 1,200 customers of
varying sizes in 50 different countries.
Growth via M&A, but this team has successfully run this playbook before.
CEO Jack McDonald and CFO Mike Hill have successfully executed the
consolidation strategy before as the executive team at Perficient (PRFT :
NASDAQ), an IT services firm. They have proven themselves to be
disciplined acquirers and have identified targets, this time in the software
market, that go largely unnoticed by other potential acquirers.
Target market upgrading from legacy or siloed apps. Upland’s suite of
software products addresses a market that is currently dominated by
legacy system software and/or ad hoc spreadsheet-based processes. This
market is moving its processes to the cloud and Upland looks well
positioned to benefit from this upgrade cycle in years to come.
UPLD shares are relatively inexpensive. The stock is currently valued at
2.3x EV/revenues based on our C2015 estimates, which is reasonably
inexpensive by most standards and a discount to our assembled comp set.
With disciplined M&A execution and moderate organic growth, there is a
legitimate case for multiple expansion in the future.
Posted by jackbassteam on December 3, 2014
ORCL : NASDAQ : US$38.27
Oracle develops, licenses and services database and
middleware software, applications software, and
hardware systems worldwide. The firm is the world’s
second largest application software firm, and a top five
systems vendor. Oracle was founded in 1977 and is
headquartered in Redwood City, CA.
All amounts in US$ unless otherwise noted.
Technology — Enterprise Software — Infrastructure
A MYTHBUSTER-THEMED ORACLE ANALYST DAY
Our view on Oracle is simple: the company is not as troubled as the stock’s
valuation reflects. There are enough good things – new products, new
markets, new business models – coming down the pipe that we expect ORCL
shares to see a 1-2 multiple point expansion over the next year, which implies
10-20% upside from here. For a large cap stock, that is more than sufficient to
justify our BUY rating.
Oracle’s analyst day as part of its OpenWorld
User Conference. A couple hundred financial types were in the room.
Incremental takeaways. The firm outlined and explained multiple
attributes that are better than consensus opinion – in other words, Oracle
was busting myths. The firm’s near-term ARR cloud pipeline tops $2
billion and is growing 30%+, meaningful upgrades in the firm’s core,
highly profitable database are on tap, and financial engineering in terms
of share count repurchases will remain material and fairly aggressive.
Why the stock works. One way to make money in stocks is to buy shares
of companies on which investors soften too bearish opinions. This is the
crux of our BUY rating on ORCL. Yes, Oracle has vibrant competition, but
the firm simply is not as endangered, at least in the next year or so, as
hyperventilating cloud competitors assert. We have seen meaningful
rallies for Microsoft and HP as investor perception went from dire to at
least neutral. We believe a similar transformation awaits ORCL shares.
Valuation and price target
Our unchanged $48 price target is based on a 13x multiple applied to our
F2016 non-GAAP EPS estimate of $3.26 plus approximately $5.00 in
prospective net cash per share
Posted by jackbassteam on October 3, 2014
GOOG : NASDAQ
Target: US$1,000.00 PLUS
Technology — Internet
SOLID Q3 RESULTS
Google reported solid Q3 results that beat consensus for revenue and EPS by a few percent despite intra-quarter concerns that the rollout of Enhanced Campaigns would negatively impact advertiser behavior in the quarter. Websites revenue growth accelerated despite continued CPC shrinkage and made up for a big deceleration in Network revenue. With many investors already expecting a strong Q4 from EC impact, getting past this potentially bumpy Q3 with a solid set of results should allow the stock to work well through year-end.
Bullish – Websites revenue growth accelerated to 22% from 18% in Q2 (albeit against an easy comp); positive TAC developments – network TAC was 70.5% of revenue, down from 72.3% in Q2 despite weaker Network revenue, which typically sheds low-TAC partners, and Web sites TAC was 8%, flat with Q2 and better than our estimate.
Bearish – CPCs shrunk another 8% y/y as mobile/EC transition continues; Network revenue growth slowed to near zero y/y, decelerating sharply from a weak 7% in Q2; MMI lost >$300 million.
Estimate changes – We are changing our 2013/2014/2015 combined gross revenue estimates to $59.4B/$67.8B/$77.9B from $59.4B/$68.6B/$78.6B and increasing non-GAAP EPS estimates to $44.37/$53.14/$64.04 from $43.99/$52.54/$62.99.
We raise our price target to $1,000 PLUS from $940. Our new target is based on 19x (up from 18x) our slightly higher 2014 non-GAAP EPS estimate of $53.14 (up from $52.54).
Posted by jackbassteam on October 28, 2013
Image via CrunchBase
NASDAQ : US$4.52 BUY
Mitel is a premier provider of IP telephony infrastructure, principally to small and mid-size organizations characterized by 1,000 or fewer lines. Products include IP-PBX systems, desktop hardware, UCC applications and managed services. Based in Ottawa, Canada, Mitel employs ~2,400 individuals and has 1,600 channel partners across 90 countries.
All amounts in US$ unless otherwise noted.
Semiconductor Devices and Related Technologies
UPSIDE LIKELY ON EXPANDING SOFTWARE SALES
We reiterate our BUY rating and increase our price target to $6 from $5 following largely in line Jul Q results and healthy gross margin guidance.
While the outlook for Oct Q revenue is a little light versus our previous model, gross margin expansion is proceeding at a strong clip, and we expect MITL to further capitalize on traction for its MiCloud UC-as-aservice offering and recently-acquired prairieFyre’s contact center solution. We continue to view MITL as well positioned in leading virtualized UC applications and see upside potential to our estimates on continued gross margin expansion driven by expanding software sales.
MITL reported Q2/C13 (Jul) results. Revenue was $141.6 million compared to our estimate of $142.5 million and consensus of $143.5 million. EPS was $0.17, compared to our inline estimate of $0.15.
Management guided Q3/C13 (Oct) to revenue of $142-148M, and implied EPS at the mid-point of $0.19. This compared to consensus estimates of $149M/$0.21 and our estimate of $148M/$0.21.
Management highlighted that the guidance includes caution based on the softness seen by Avaya and Cisco.
Mitel completed the acquisition of prairieFyre, a contact center software provider, for $20 million in cash in the quarter.
prairieFyre provides Mitel’s existing contact center solutions and management highlighted the acquisition was accretive in the quarter.
MITL’s price target of $6 (was $5) is 6x our C2014 EPS estimate of $.95
Posted by jackbassteam on August 30, 2013
AVGO : NASDAQ : US$36.56
Avago Technologies Limited is a designer, developer and global supplier of analog semiconductor devices. Avago offers products in three primary target markets: wireless communications, wired infrastructure, and industrial and automotive electronics. Applications for Avago products include smartphones, connected tablets, consumer appliances, data networking and telecom equipment, and enterprise storage and servers.
Technology — Communications Technology — Semiconductors
STRONG Q3/F13 RESULTS; WIRELESS AND WIRED DIVISIONS DRIVE STRONG Q4/F13 GUIDANCE
Avago reported strong Q3/F13 results above our estimates with strong Wired and Industrial division sales offsetting weaker-than-expected Wireless demand. Further, Avago guided to strong sequential sales growth in Q4/F13 driven by strong
trends in the company’s Wireless and Wired divisions. We believe Avago’s proprietary technologies, strong IP portfolio, and diverse customer base in several growth markets position the company for strong long-term growth trends with industry-leading margins.
We reiterate our BUY rating and increase our price target to $45.
Q3/F13 sales of $644M and pro forma EPS of $0.74 were above our $623M/$0.68 estimates driven by 18% Q/Q sales growth in the higher-margin Industrial and Wired Infrastructure (excluding CyOptic sales) divisions versus our mid-single digit growth estimates for each division. CyOptics contributed $21M in sales during the quarter and should contribute $55M in Q4.
Wireless sales increased only 3% sequentially or below management’s high-single digit sequential growth guidance, but
this is consistent with our analyses indicating softer high-tier smartphone sales trends during Q3/F13.
Avago management guided to a 12-15% Q/Q sales increase for Q4/F13 driven by solid Q/Q growth in the Wireless and Wired Infrastructure divisions. Management anticipates mid-teens percent Q/Q growth in the Wireless division due to sales ramping into new smartphone programs at both Apple and Samsung, as Avago is benefitting from increased content share in high-end LTE smartphones.
Given the strong results and our expectations for sustained growth trends, we have increased our F2013 pro forma EPS from $2.76 to $2.82 and F2014 from $3.29 to $3.30.
Valuation: Our $45 price target is based on shares trading at roughly 13x – 14x our F2014 pro forma EPS estimate.
Posted by jackbassteam on August 28, 2013
Urban Outfitters in Pasadena, California (Photo credit: Wikipedia)
Urban Outfitters is a specialty retail offering fashion apparel, accessories, and home goods through around 490 stores, online,
and catalogs. The company operates under the Urban Outfitters, Anthropologie, Free People (which includes a wholesale
segment), Terrain, and BHLDN brands.
All amounts in US$ unless otherwise noted
URBN’s Q2 EPS of $0.51 beat our $0.47 estimate and consensus of $0.48. Despite comparable retail sales growth 160bps ahead of our forecast at +9% on top of +4%, total sales growth of 12% was below our +13% estimate. URBN opened fewer new Free People stores than we had anticipated, and Terrain’s landscape business declined. The EPS upside was driven by a better gross margin as fewer markdowns at Anthropologie drove a 168bps expansion versus our +86bps estimate.
The S.G. & A. expense rate increased 14bps, better than our forecast of 60bps of deleverage. Shares are trading at 19x our 2014 EPS estimate and 9x 2014E EV/EBITDA based on the after-hours quote of $42. We view these as fair multiples for a retailer we project will grow its top and bottom lines at average rates of 9% and 13%, respectively, over the next five years.
We are raising our Q3 EPS estimate by $0.01 to $0.46, a penny below prior consensus. Our model calls for a 105bps gross margin increase, up from our prior forecast of a 55bps improvement. For 2013, a 40bps increase in our gross margin projection lifts our EPS estimate by $0.06 to $1.90, $0.01 below consensus.
Incorporating our updated estimates into our DCF model and rolling it out to 2014 raises our price target from $41 to $48
Posted by jackbassteam on August 20, 2013
NASDAQ : US$54.18
Steven Madden, Ltd., together with its subsidiaries, designs, sources, markets and sells fashion-forward footwear for women, men and children. The company was founded in 1990 and is headquartered in Long Island City, New York. SHOO has a portfolio of brands that reaches globally among all economic tiers. SHOO offers products through wholesale partners, an e-commerce
platform and its own retail stores.
All amounts in US$ unless otherwise noted.
CEO Ed Rosenfeld presented at the Canaccord Global Growth Conference Wednesday.
Central to its strategy is (1) accelerating growth in the core Steve Madden women’s business from MSD to M-HSD, (2) expanding outlet door openings, and (3) market share gains with both new and existing brands. While still early, the reads on BTS have been positive and retailers are enthusiastic about the newness for fall ‘13 particularly in booties/boots. We reiterate our BUY rating and raise our target to $59 from $57 to reflect a slightly higher P/E multiple of 15x in our valuation.
SHOO continues to take share at M and as such its table doors dedicated solely to the Steve Madden brand are expanding by 13% from 230 to 260 this fall. Any weakness at M is not affecting SHOO.
Emerging brands (Betsey, Superga, and Freebird) are all performing well and have ample growth runway ahead. With the recent upturn in dress shoes, Betsey footwear growth should accelerate into 2014. Growth of outlet stores (12 currently) could accelerate next year as SHOO sees an opportunity to ultimately have 50-60 stores.
Our $59 target is a blend of 15x 2014E EPS, 9x EBITDA, and DCF.
Posted by jackbassteam on August 16, 2013
Production of pyocyanin, water-soluble green pigment of Pseudomonas aeruginosa. (left tube) Ps. aeruginosa cultured on heart infusion soft agar medium. The aerobic bacteria grow only on the surface of the medium (forming whitish biofilm) , and water-soluble green pigment diffuses down. (right tube) Uninnoculated medium (as control). (Photo credit: Wikipedia)
NASDAQ : US$10.87 BUY
Insmed is focused on developing novel, targeted inhaled therapies for the treatment of serious orphan lung diseases. Its lead product candidate is Arikace, a liposomal formulation of FDA approved antibiotic, amikacin.
All amounts in US$ unless otherwise noted.
Reiterate BUY, $18 price target on Arikace potential in two orphan indications: CF P. aeruginosa and nontuberculous
mycobacteria (NTM) lung infections. INSM’s lead drug Arikace is a liposomal formulation of potent, FDA-approved antibiotic
amikacin. We expect positive data from a Phase 2 US NTM trial (data Q1/14E). Our $18 target is based on a pNPV analysis.
We continue to see the NTM as the value drive of the stock and think a clear path forward will crystallize after Q1 date
and formal FDA meeting along with ongoing QIDP dialogue.
INSM believes a single point change in the NTM endpoint scale would be clinically meaningful. We think if a one-point
change on the 7-point, semi-quant scale is supported by improvements in QoL measures, this combination of data
could be meaningful to FDA and clinicians. Data from the Ph2 open label trial should be available mid-2014.
We think Ph3 CF sub-population analysis could support European health technology assessments. Sub-population
analysis from CF Ph3, to be presented at NACFC, could support Arikace use in certain select patient populations either instead of or in combination with Tobi.
Posted by jackbassteam on August 15, 2013